Peps
What is Vosoritide?
Vosoritide is a C-type natriuretic peptide analogue studied for growth in children with achondroplasia. Its disease-specific evidence does not support height-increase claims for healthy adults.
Biological role or research focus
Growth research in achondroplasia.
This report did not establish final adult height or long-term functional outcomes. It does not apply to healthy adults with closed growth plates.
Names you may encounter
BMN 111 · Voxzogo
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- C-type natriuretic peptide analogue
- Research focus
- Growth research in achondroplasia
- Featured evidence
- Human randomized phase 3 trial
- Source check
- October 4, 2026
Biology & proposed mechanism
The approach modulates growth-plate signaling in the context of FGFR3-associated achondroplasia. The presence of functioning growth plates and the diagnosis are central to interpretation.
Medicine status & clinical context
Vosoritide is a prescription C-type natriuretic peptide analog used to increase linear growth in certain children with achondroplasia. Eligibility comes from the current product information; it is not a height-enhancement indication for healthy adults.
The featured publication concerns children with achondroplasia. Current product eligibility and precautions require the relevant prescribing reference.
Source: MedlinePlus · Vosoritide ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized phase 3 trial · 2020
Vosoritide in children with achondroplasia
What did this publication test, and what did it find?
- Population / model
- 121 children aged five to under 18 years with achondroplasia.
- Study design
- 52-week randomized masked phase 3 study: 60 received vosoritide and 61 placebo.
- Main finding
- Adjusted annualized growth velocity was 1.57 cm/year higher with vosoritide, with a 95% CI of 1.22–1.93 cm/year.
- Limits & context
- This report did not establish final adult height or long-term functional outcomes. It does not apply to healthy adults with closed growth plates.
Human randomized trial · 2024
Vosoritide · children younger than five
What happened in the younger-child trial?
- Population / model
- 75 children aged 3–59 months with achondroplasia: 11 sentinel participants and 64 randomized participants.
- Study design
- 52-week double-blind placebo comparison with safety and height Z-score outcomes.
- Main finding
- The between-group height Z-score difference was 0.25 (95% CI −0.02 to 0.53). Adverse events occurred in all participants, mostly injection-site reactions; a death occurred in the treated group.
- How to read it
- The confidence interval includes no difference. Listing an event in the treated group does not establish drug causation.
- Limits & context
- Small groups, young age, and one-year follow-up limit precision and assessment of uncommon harms. Growth measures do not establish improvement in every complication of achondroplasia. BioMarin funded the trial.
Human open-label extension · 2021
Vosoritide · two-year extension
Did the growth signal continue after the blinded trial?
- Population / model
- Children completing a phase 3 achondroplasia trial; the abstract does not provide the extension sample size.
- Study design
- All extension participants received vosoritide, including children crossing over from placebo.
- Main finding
- Annual growth velocity in the originally treated group was 4.26 cm/year at baseline, 5.39 at week 52, and 5.52 at week 104. No new adverse effects were detected in the reported period.
- How to read it
- Growth velocity describes a rate; it is not a measure of final adult height.
- Limits & context
- The extension lacks a concurrent placebo group and includes trial completers. No new detected effects is not proof of absence of rare or long-term harms.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 2 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. ↗
EClinicalMedicine · 2024 May · Journal Article
Read available full text ↗
Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. ↗
Med (New York, N.Y.) · 2025 May 9 · Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Clinical use requires the product’s monitoring and precaution framework. A one-year trial cannot exclude uncommon or delayed harms.
Evidence boundaries
This report did not establish final adult height or long-term functional outcomes. It does not apply to healthy adults with closed growth plates.
Official product context · checked October 4, 2026
Temporary blood-pressure reductions, injection-site reactions, and other adverse effects are described in the medication information. Growth monitoring and relevant heart or kidney history form part of the clinical context.
Source: MedlinePlus · Vosoritide ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Does this trial support height increases in healthy adults?
- What material, population, and route were actually studied?
- This report did not establish final adult height or long-term functional outcomes. It does not apply to healthy adults with closed growth plates.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does this trial support height increases in healthy adults?
No. It enrolled growing children with achondroplasia, and did not establish an effect in adults with closed growth plates.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
Source: MedlinePlus · Vosoritide ↗
References & editorial record
- PubMed · PMID 32891212 ↗
- MedlinePlus · Vosoritide ↗
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. ↗
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.